Effect of RAS inhibition on TGF-β, renal function and structure in experimentally induced diabetic hypertensive...

Area of Science:

• Nephrology
• Pharmacology
• Endocrinology

Background:

• Diabetic nephropathy pathogenesis involves transforming growth factor-beta (TGF-β) and fibrogenic signals.
• Developing antifibrotic agents is crucial for managing diabetic nephropathy.

Purpose of the Study:

• To evaluate the efficacy of spironolactone and moexipril, alone and in combination, in treating diabetic nephropathy in rats.
• To assess the impact of these treatments on renal function, fibrosis, and key molecular markers.

Main Methods:

• Fifty rats were divided into five groups: control, diabetic hypertensive, and diabetic hypertensive rats treated with spironolactone, moexipril, or both.
• Measurements included serum creatinine, mean arterial blood pressure (MAP), aldosterone, angiotensin-converting enzyme (ACE), TGF-β, and renal fibrosis.

Main Results:

• Untreated diabetic hypertensive rats showed significantly elevated serum creatinine, MAP, aldosterone, ACE, TGF-β, and renal fibrosis compared to controls.
• Treatment with spironolactone, moexipril, or the combination reduced these pathological changes.

Conclusions:

• Combination therapy with spironolactone and moexipril demonstrated superior efficacy in reducing renal fibrosis and improving renal function compared to monotherapy.
• This enhanced effect is likely due to a dual inhibition of the renin-angiotensin system (RAS), leading to TGF-β suppression.